ImmunoGen (IMGN) Initiates IMGN901 Phase II
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Join SI Premium – FREE
ImmunoGen, Inc. (Nasdaq: IMGN) has initiated Phase II testing of its IMGN901 product candidate for first-line treatment of SCLC.
The Phase II assessment begun today, also known as the NORTH trial, is designed to evaluate whether the addition of IMGN901 to standard first-line care for SCLC meaningfully impacts duration of progression-free survival (PFS). With SCLC, the efficacy of first-line treatment is considered to be particularly important due to the low likelihood of obtaining a marked, sustained response with any subsequent treatment.
The Phase II assessment begun today, also known as the NORTH trial, is designed to evaluate whether the addition of IMGN901 to standard first-line care for SCLC meaningfully impacts duration of progression-free survival (PFS). With SCLC, the efficacy of first-line treatment is considered to be particularly important due to the low likelihood of obtaining a marked, sustained response with any subsequent treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Nu Skin EVP of global sales takes medical leave
- Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
